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Introduction. For many years warfarin was the drug of choice for the prevention of 
thromboembolic complications in patients with AF. But warfarin therapy has some difficulties, 
including a narrow therapeutic window and the need for continuous laboratory monitoring. In the 
last decade, many scientific studies have been devoted to the impact of the genetic characteristics of 
the patient, in particular, CYP2C9 and VKORC1 gene polymorphism, on warfarin therapy. 
Methods. We examined 50 patients with AF of Kazakh nationality who underwent genetic 
testing to study the relationship between gene polymorphisms and the therapeutic dose of warfarin. 
Results. Among the studied patients the most common genotype of the CYP2C9*2 gene was 
the "wild" CC genotype - 74% (n = 37) and 26% (n = 13) of patients had heterozygous CT 
genotype. Also 92% of the patients were carriers of the "wild" AA genotype of CYP2C9*3 gene. 
For patients with the CC genotype of the CYP2C9*2 gene the daily dose of warfarin was 3.88 ± 
0.3 mg, and for patients with CT genotype- 3,22 ± 0,5 mg (p = 1.02). The dose of warfarin for 
carriers of the "wild" AA genotype of CYP2C9*3 gene was 3.79 ± 0.27 mg, and for carriers of the 
heterozygous AC variant- 3.59 ± 0.35 mg (p = 0.74). So, there was no statistically significant 
difference in the average therapeutic dose of warfarin in patients with different genotypes of 
CYP2C9*2 and CYP2C9*3. Among the studied patients the most common genotype of the 
VKORC1C1173T gene was heterozygous CT genotype- 56%, the TT genotype was in 38% of 
patients and wild genotype (CC) 6% of patients. When analyzing the dose of warfarin, depending 
on the polymorphism of the gene VKORC1C1173T, it was established that in the carriers of the 
"wild" CC genotype the dose of warfarin was 6.25 ± 1.56 mg, which is almost 2 times higher than 
in homozygous carriers of the mutant allele TT- 2.99 ± 0.29 mg (p <0.05). 
Conclusions. The patients of Kazakh nationality with the mutant allele of the 
VKORC1C1173T gene needs in lower therapeutic doses of warfarin. 
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